Login / Signup

Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft tissue sarcoma: a prospective, single-arm phase II study.

Xin LiuYuankai ShiHuijie WangXianghua WuWangjun YanYong ChenYu XuChunmeng WangWeiqiang YaoJian WangLin YuJiashun MiaoHao ChenJing XiaMengli HuangXiaowei ZhangZhiguo Luo
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Combination therapy comprising PLD and IFO is an effective and well-tolerated first-line treatment for patients with advanced or metastatic STS.
Keyphrases
  • combination therapy
  • phase ii study
  • squamous cell carcinoma
  • small cell lung cancer
  • locally advanced
  • open label
  • drug delivery
  • cancer therapy
  • placebo controlled
  • randomized controlled trial
  • radiation therapy